Literature DB >> 25063008

Treatment of clinical T2N0M0 esophageal cancer.

Wayne Hofstetter1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25063008     DOI： 10.1245/s10434-014-3935-8

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN： 1068-9265            Impact factor:   5.344


× No keyword cloud information.
  5 in total

1.  Comparative effectiveness of upfront esophagectomy versus induction chemoradiation in clinical stage T2N0 esophageal cancer: A decision analysis.

Authors:  Tara R Semenkovich; Roheena Z Panni; Jessica L Hudson; Theodore Thomas; Leisha C Elmore; Su-Hsin Chang; Bryan F Meyers; Benjamin D Kozower; Varun Puri
Journal:  J Thorac Cardiovasc Surg       Date:  2018-01-12       Impact factor: 5.209

2.  Patterns of Use of Induction Therapy for T2N0 Esophageal Cancer.

Authors:  Kristen E Rhodin; Vignesh Raman; Oliver K Jawitz; Soraya L Voigt; Norma E Farrow; David H Harpole; Betty C Tong; Thomas A D'Amico
Journal:  Ann Thorac Surg       Date:  2020-07-15       Impact factor: 4.330

3.  A Clinical Nomogram for Predicting Node-positive Disease in Esophageal Cancer.

Authors:  Tara R Semenkovich; Yan Yan; Melanie Subramanian; Bryan F Meyers; Benjamin D Kozower; Ruben Nava; G Alexander Patterson; Daniel Kreisel; Varun Puri
Journal:  Ann Surg       Date:  2021-06-01       Impact factor: 13.787

4.  Development and validation of nomograms to intraoperatively predict metastatic patterns in regional lymph nodes in patients diagnosed with esophageal cancer.

Authors:  Fei Zhao; Rong-Xin Lu; Jin-Yuan Liu; Jun Fan; Hao-Ran Lin; Xiao-Yu Yang; Shu-Hui You; Qian-Ge Wu; Xue-Yun Qin; Yi Liu; Fu-Xi Zhen; Jin-Hua Luo; Wei Wang
Journal:  BMC Cancer       Date:  2021-01-05       Impact factor: 4.430

5.  Prognostic Value of CT Imaging-Based Tumor Volume in Patients With Non-Surgical Esophageal Squamous Cell Carcinoma.

Authors:  Ning Kang; Yeying Fang; Huijun Zhu; Zhiling Shi; Liuyin Chen; YuShuang Lu; Housheng Wang; Jiamei Lu; Wenqi Liu; Kai Hu
Journal:  Front Oncol       Date:  2021-01-22       Impact factor: 6.244
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.